← The Wire
NRIXNasdaq
Nurix Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1549595
Nurix Therapeutics discovers, develops, and commercializes targeted protein degradation medicines for cancer and inflammatory diseases
🔥 High media attention
$1.75B
Market cap
$23.85
Last close
+4.2%
1D
+27.9%
5D
2.7M
Volume
Price · last 39 sessions+40.9%
May 4L $14.64 · H $23.85Jun 29
143
Total filings
Jun 11, 2026
Last filing
11/30
Fiscal year end
SC 13GSEC SCHEDULE 13GNov 8, 2024SC 13GSCHEDULE 13GFeb 14, 2024SC 13GSCHEDULE 13GFeb 13, 2024SC 13GMS INITIALFeb 9, 2024SC 13GSC 13GJan 29, 2024SC 13GSC 13GFeb 24, 2023SC 13GSC 13GFeb 10, 2023SC 13GSC 13GFeb 8, 2023SC 13GSC 13GJun 10, 2022SC 13GSC 13GFeb 14, 2022SC 13GSC 13GFeb 4, 2022SC 13GSC 13GAug 10, 2021SC 13GSC 13GFeb 16, 2021SC 13GSC 13GFeb 16, 2021SC 13GSC 13GFeb 16, 2021SC 13GSEC SCHEDULE 13GAug 10, 2020SC 13GSC 13GAug 3, 2020
Insider Activity
In the 90 days to Mar 2, 2026: 3 sold $715K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 2, 2026 | Ring ChristineChief Legal Officer | Sell | 8,148 | $15.44 | $126K |
| Feb 9, 2026 | Ring ChristineChief Legal Officer | Sell | 14,261 | $16.66 | $238K |
| Jan 30, 2026 | Hansen GwennChief Scientific Officer | Sell | 4,797 | $16.58 | $80K |
| Jan 30, 2026 | Ring ChristineChief Legal Officer | Sell | 4,333 | $16.58 | $72K |
| Jan 30, 2026 | Van Houte HansChief Financial Officer | Sell | 3,588 | $16.58 | $59K |
| Jan 30, 2026 | Hansen GwennChief Scientific Officer | Sell | 98 | $17.37 | $2K |
| Jan 30, 2026 | Ring ChristineChief Legal Officer | Sell | 88 | $17.37 | $2K |
| Jan 30, 2026 | Van Houte HansChief Financial Officer | Sell | 73 | $17.37 | $1K |
| Jan 20, 2026 | Ring ChristineChief Legal Officer | Sell | 3,760 | $18.42 | $69K |
| Dec 18, 2025 | Ring ChristineChief Legal Officer | Sell | 3,560 | $17.87 | $64K |
| Dec 18, 2025 | Ring ChristineChief Legal Officer | Sell | 200 | $18.56 | $4K |
| Nov 24, 2025 | Ring ChristineChief Legal Officer | Sell | 37,600 | $17.07 | $642K |
| Nov 3, 2025 | Van Houte HansChief Financial Officer | Sell | 6,284 | $12.56 | $79K |
| Oct 30, 2025 | Hansen GwennChief Scientific Officer | Sell | 4,087 | $12.80 | $52K |
| Oct 30, 2025 | Ring ChristineChief Legal Officer | Sell | 3,644 | $12.80 | $47K |
| Oct 30, 2025 | Van Houte HansChief Financial Officer | Sell | 3,130 | $12.80 | $40K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
🔥 High media attentionCoverage (30d): 4 reputable articles · skews ▲ positive.
Investor's Business DailyRoche Inks $2.3 Billion Deal, Sending This Small Biotech Stock Flying21d agoBarron'sThis Biotech Stock Is Popping 10% on $2.3 Billion Roche Deal for Blood Cancer Drug21d agoReutersRoche enters cancer drug deal worth up to $2.3 billion with Nurix Therapeutics22d agoWSJRoche Licenses Nurix Therapeutics Blood-Cancer Drug for Up to $2.3 Billion22d ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance